J Med Microbiol NEW Faster Access
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Roesler, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Roesler, J.
Agricola
Right arrow Articles by Roesler, J.
J Med Microbiol 56 (2007), 1253; DOI: 10.1099/jmm.0.47250-0
© 2007 Society for General Microbiology
ISSN 1473-5644


Correspondence

Important role of corticosteroids in chronic granulomatous disease

Joachim Roesler

University Clinic Carl Gustav Carus, Department of Pediatrics, Fetscherstr. 74, 01307 Dresden, Germany

Correspondence
Joachim Roesler
(roeslerj{at}rcs.urz.tu-dresden.de)


Recently, Arimura et al. (2006) published an interesting case report about a disseminated lethal varicella-zoster virus infection in a patient with chronic granulomatous disease (CGD) who suffered from CGD-associated inflammatory bowel disease (IBD), and was therefore treated with high doses of corticosteroids. The authors point out an important potential side effect of steroids that is not related to CGD. CGD patients are not more susceptible to viral infections than healthy individuals. The authors conclude properly that IBD secondary to CGD should be differentiated from idiopathic IBD.

However, the second part of the authors’ conclusion stating that immunosuppressive drugs, including corticosteroids, should be avoided in the treatment of CGD is inappropriate and unjustified. On the contrary, steroids play an important role in the treatment of CGD in several respects.

Relatively high doses of steroids [in the range of 1 mg prednisolone (kg body weight)–1 daily] in addition to appropriate antimicrobial treatment can be life saving when CGD patients have inhaled Aspergillus spores that germinate in the airways and cause a clinical picture strongly resembling severe hypersensitivity pneumonitis (S. M. Holland, unpublished results). The anti-inflammatory treatment can prevent the need for artificial respiration and the development of adult respiratory distress syndrome. Some authors consider using steroids in cases of refractory opportunistic infections in CGD provided antimicrobial drugs are sufficiently administered (Okano et al., 1999; Yamazaki-Nakashimada et al., 2006). This can be helpful because CGD patients tend to develop granulomas, pronounced inflammatory infiltrates, thick walls around abscesses and organ fibroses. Steroids can confine such deleterious inflammation.

In CGD inflammatory infiltrates, granuloma formation and fibroses can also occur in the absence of overt infection, and can be organ damaging and even life threatening. Again steroids are an important option after opportunistic infections are excluded as carefully as possible and under appropriate prophylaxis (Roesler et al., 2005). CGD-associated urinary obstructions and IBD also remain established indications for the use of steroids because side effects as described by Arimura et al. (2006) are rare and not specific for CGD (Marciano et al., 2004; Danziger et al., 1993). Finally, low doses of steroids may be helpful in treating loss of appetite and weight loss due to subclinical IBD, in treating disturbed wound healing and anal fistula formation.

Arimura et al. (2006) mention bone marrow transplantation and gene therapy as alternatives to immunosuppression in CGD. However, many CGD patients are doing remarkably well when under regular surveillance and prophylaxis. The prognosis with conventional therapy can be characterized as fair (ESID, 2006). Bone marrow transplantation is an option for patients with persisting problems, but remains risky. Pros and cons are difficult to assess, and it requires a human leukocyte antigen-matched donor. Gene therapy is certainly desired, but far from applicable as a routine approach.

REFERENCES

Arimura, Y., Goto, A., Yamashita, K., Endo, T., Ikeda, H., Tanaka, K., Tsutsumi, H., Shinomura, Y. & Imai, K. (2006). Intractable colitis associated with chronic granulomatous disease. J Med Microbiol 55, 1587–1590.[Abstract/Free Full Text]

Danziger, R. N., Goren, A. T., Becker, J., Greene, J. M. & Douglas, S. D. (1993). Outpatient management with oral corticosteroid therapy for obstructive conditions in chronic granulomatous disease. J Pediatr 122, 303–305.[Medline]

ESID (2006). European Society of Immunodeficiency Disease Meeting, Budapest, Hungary, 4–7/10/2006.

Marciano, B. E., Rosenzweig, S. D., Kleiner, D. E., Anderson, V. L., Darnell, D. N., Anaya-O'Brien, S., Hilligoss, D. M., Malech, H. L. & other authors (2004). Gastrointestinal involvement in chronic granulomatous disease. Pediatrics 114, 462–468.[Abstract/Free Full Text]

Okano, M., Yamada, M., Ohtsu, M., Kawamura, N., Sakiyama, Y., Aoi, K., Gandoh, S., Fujita, M. & Kobayashi, K. (1999). Successful treatment with methylprednisolone pulse therapy for a life-threatening pulmonary insufficiency in a patient with chronic granulomatous disease following pulmonary invasive aspergillosis and Burkholderia cepacia infection. Respiration 66, 551–554.[CrossRef][Medline]

Roesler, J., Koch, A., Porksen, G., von Bernuth, H., Brenner, S., Hahn, G., Fischer, R., Lorenz, N., Gahr, M. & Rosen-Wolff, A. (2005). Benefit assessment of preventive medical check-ups in patients suffering from chronic granulomatous disease (CGD). J Eval Clin Pract 11, 513–521.[CrossRef][Medline]

Yamazaki-Nakashimada, M. A., Stiehm, E. R., Pietropaolo-Cienfuegos, D., Hernandez-Bautista, V. & Espinosa-Rosales, F. (2006). Corticosteroid therapy for refractory infections in chronic granulomatous disease: case reports and review of the literature. Ann Allergy Asthma Immunol 97, 257–261.[Medline]




This article has been cited by other articles:


Home page
J Med MicrobiolHome page
Y. Arimura, A. Goto, K. Yamashita, T. Endo, H. Ikeda, K. Tanaka, H. Tsutsumi, Y. Shinomura, and K. Imai
Authors' reply to 'Important role of corticosteroids in chronic granulomatous disease'
J. Med. Microbiol., September 1, 2007; 56(9): 1254 - 1254.
[Full Text] [PDF]


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Roesler, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Roesler, J.
Agricola
Right arrow Articles by Roesler, J.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
INT J SYST EVOL MICROBIOL J MED MICROBIOL MICROBIOLOGY J GEN VIROL ALL SGM JOURNALS